# Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

> **NCT03567499** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** GSK3039294
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03567499
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-12
- **Primary completion:** 2019-05-03
- **Final completion:** 2019-05-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision to end the study was made for GSK portfolio reasons. No subjects were randomised into the study.
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567499, "Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03567499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*